- Home
- MVST vs ERAS Comparison
MVST vs ERAS Comparison
Compare MVST & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | ERAS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.0M | 927.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVST | ERAS |
|---|---|---|
| Price | $2.94 | $3.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $6.00 | $3.71 |
| AVG Volume (30 Days) | ★ 4.9M | 2.3M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,504,000.00 | N/A |
| Revenue This Year | $24.14 | N/A |
| Revenue Next Year | $28.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $1.08 | $1.01 |
| 52 Week High | $7.12 | $3.80 |
Technical Indicators
Market Signals| Indicator | MVST | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 65.58 |
| Support Level | $3.28 | $3.34 |
| Resistance Level | $3.03 | $3.80 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.43 | 76.77 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.